Uromed (US) launches incontinence device in Germany:
This article was originally published in Clinica
Uromed (US) is to launch its Reliance Insert incontinence device in Germany this autumn. The single-use, balloon-tipped device is inserted into the urethra with a reusable applicator which, when depressed, inflates the balloon. The insert is removed to allow urination by pulling on a string which deflates the balloon. Average use is expected to be three times daily. The Reliance is indicated for stress urinary incontinence for patients unwilling to undergo surgery or as a stopgap before surgery. UroMed has filed for a 510(k) in the US and hopes to launch the device in other countries this year. Some 8.5 million women in the US suffer urinary incontinence.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.